reports
PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement ...
PLx Pharma Inc. Enters into a Stalking Horse Asset Purchase Agreement to Sell VAZALORE® and Substantially All of its Assets SPARTA, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ and VAZALORE®, an FDA-approved liquid-filled aspirin capsule, available in 81 mg and 325 mg doses. The Company today announced that it entered into a stalking horse asset purchase agreement (the “APA”) with PLx Acquisition Company, LL...
PLx Pharma Inc. Receives Nasdaq Delisting Notice
PLx Pharma Inc. Receives Nasdaq Delisting Notice SPARTA, N.J., April 11, 2023 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company had previously announced that on October 3, 2022, it was notified by the Listing Qualifications Department (the “Listing Qualifications De...
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Busine...
PLx Pharma Inc. Reports Third Quarter 2022 Results and Provides Business Update - Significant Reduction in Operating Expenses - Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Q3 2022Total Operating Expenses Significantly Lower by $2.8 Million, or 22%, in Q3 2022 vs. Q3 2021; $4.4 Million or 31% Lower Sequentially vs. Q2 2022GAAP Net Loss of ($0.30) Per Diluted Share in Q3 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.37)Cash ...
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on Nove...
PLx Pharma Inc. to Report Third Quarter 2022 Financial Results on November 11, 2022, and Provide Business Update SPARTA, N.J., Oct. 26, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled asp...
Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels
Baseball Legend John Smoltz Featured on PLx Pharma’s Social Channels Legendary Baseball Pitcher and Avid Golfer Uses VAZALORE® 325 mg for Fast, Effective Pain Relief SPARTA, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead produ...
Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81...
Survey: Cardiovascular Patients on Aspirin Therapy Prefer VAZALORE® 81 mg Results of National Patient Experience Survey Show 95% Satisfaction Rate with VAZALORE 81 mg as Aspirin Therapy Choice FDA-Approved VAZALORE Delivers Fast, Reliable Absorption of Aspirin SPARTA, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the mark...
PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Busin...
PLx Pharma Inc. Reports Second Quarter 2022 Results and Provides Business Update - Initiates Evaluation of Strategic Alternatives to Enhance Stockholder Value - Reports Positive Results of VAZALORE® 81 mg Patient Experience Survey - Streamlines Sales & Marketing Plan Total Net Sales of $0.5 Million, Including $0.4 Million of Unfavorable Adjustments for Additional Trade Allowances and Incremental Sales Returns Reserves in Second Quarter of 2022Total Operating Expenses Were Lower by $4.9 Million in Second Quarter of 2022 vs. Q1 2022GAAP Net Loss of ($0.43) Per Diluted Share in Second Quart...
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August...
PLx Pharma Inc. to Report Second Quarter 2022 Financial Results August 12, 2022, and Provide Business Update SPARTA, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin...
PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Confer...
PLx Pharma Inc. to Present at JMP Securities 2022 Life Sciences Conference on June 15, 2022 SPARTA, N.J., June 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsules (referr...
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Societ...
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events SPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to red...
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Busine...
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update BUILDING A SOLID BASE OF VAZALORE® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021GAAP Net Loss of ($0.39) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ($0.66) Cash & Cash Equivalent Balance of $52.5 Million as of March 31, 2022Disciplined Spending to Support Strategic Growth SPARTA, N.J., May 13, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is...
PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May...
PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update SPARTA, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liqui...
- Jonathan Moreland
SPPI SPECTRUM PHARMACEUTICALS INC.
NRIM NORTHRIM BANCORP INC.
NGL NGL ENERGY PARTNERS LP
MMLP MARTIN MIDSTREAM PARTNERS L.P.
HZN HORIZON GLOBAL CORP.
ANIK ANIKA THERAPEUTICS INC.
AAT AMERICAN ASSETS TRUST INC.
BRC BRADY CORPORATION CLASS A
USFD US FOODS HOLDING CORP.
OCX ONCOCYTE
LIVE LIVE VENTURES
PLXP PLX PHARMA INC
SPRO SPERO THERAPEUTICS
ROOT ROOTS
SNCR SYNCHRONOSS TECHNOLOGIES
ESTA INC.
BATRA ESTABLISHMENT LABS HOLDINGS
AXLA LIBERTY BRAVES SERIES A
PWFL AXCELLA HEALTH
TELA POWERFLEET INC
BRP TELA BIO
FRG BRP GROUP
LSYN FRANCHISE GROUP
JYNT LIBERATED SYNDICATION
TARA THE JOINT
INDT PROTEON THERAPEUTICS INC
LSEA INDUS REALTY TRUST INC
ONTF LANDSEA HOMES CORP (A)
NOTV ON24
PCOR INOTIV
CTKB INC.
VWE PROCORE TECHNOLOGIES
ROVR INC.
MYPS CYTEK BIOSCIENCES INC
VINTAGE WINE ESTATES INC
ROVER METALS CORP
PLAYSTUDIOS INC
PLx Pharma Inc: 2 directors
Two Directors at PLx Pharma Inc bought 17,800 shares at between 3.653USD and 3.659USD. The significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the l...
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and ...
PLx Pharma Inc. Reports Fourth Quarter and Full Year 2021 Results and Provides Business Update Momentum Building for Novel Vazalore® Liquid-Filled Aspirin Capsules Total Net Sales of $8.2 Million in Last Five Months of 2021Net Sales of $1.6 Million in the Fourth Quarter 2021, Reflecting Timing of Trade Re-Orders Following Strong Initial Sales Distribution of VAZALORE in the Third Quarter 2021 Key Performance Measures Are Positive and Trending Higher; Company on Track and Well-Positioned to Grow Sales Substantially in 2022GAAP Net Loss of ($0.73) Per Diluted Share in Fourth Quarter 2021; Ad...
PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcar...
PLx Pharma Inc. to Present at Oppenheimer & Co’s 32nd Annual Healthcare Conference on March 15, 2022 SPARTA, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liquid-filled aspirin capsul...
PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on Ma...
PLx Pharma Inc. to Discuss 2021 Fourth Quarter Financial Results on March 11, 2022 Conference Call and Provide Business Update SPARTA, N.J., Feb. 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE 81 mg and VAZALORE 325 mg liq...
PLx Pharma Inc. Proudly Celebrates Go Red for Women Day® 2022 to Suppo...
PLx Pharma Inc. Proudly Celebrates Go Red for Women Day® 2022 to Support Heart Health Awareness -- Female-Led Company Strives to Transform Standard of Care in Secondary Prevention of Heart Attack or Clot-Related Stroke with its Innovative New Aspirin Formulation VAZALORE® -- SPARTA, N. J., Feb. 03, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the ...
PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice Pre...
PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications SPARTA, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liq...
PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Con...
PLx Pharma Inc. to Present at Piper Sandler 33rd Annual Healthcare Conference 2021 SPARTA, N.J., Nov. 22, 2021 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many drugs currently on the market and to reduce the risk of stomach injury associated with certain drugs. The Company, with its lead products VAZALORE™ 325 mg and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to t...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.